Economic evaluation of dialysis therapies

Nature Reviews Nephrology

Volumn 10, Issue 11, 2014, Pages 644-652

  Klarenbach, Scott W ^a   Tonelli, Marcello ^a   Chui, Betty ^b   Manns, Braden J ^c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BUDGET; CHRONIC KIDNEY DISEASE; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; END STAGE RENAL DISEASE; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE SYSTEM; HEMODIALYSIS; HOME DIALYSIS; HUMAN; KIDNEY TRANSPLANTATION; PERITONEAL DIALYSIS; RENAL REPLACEMENT THERAPY; REVIEW; TREATMENT OUTCOME; COST; DEVELOPED COUNTRY; DEVELOPING COUNTRY; ECONOMICS; FEE; KIDNEY FAILURE, CHRONIC; RESOURCE ALLOCATION; TIME;

COSTS AND COST ANALYSIS; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; FEES AND CHARGES; HEALTH CARE COSTS; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; RENAL DIALYSIS; RESOURCE ALLOCATION; TIME FACTORS; TREATMENT OUTCOME;

EID: 84908158745     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2014.145     Document Type: Review

References (76)

1. Lockridge R. S. J. The direction of end-stage renal disease reimbursement i. The United States. Semin. Dial. 17, 125-130 (2004).
2. Rettig R. A. & Levinsky N. G. Kidney failure an. The federal government. National Academies Press [online], http://www.nap.edu/openbook.php?record-id=1818 (1991).
3. Klarman H. E., Francis, J . O. & Rosenthal G. D. Cost effectiveness analysis applied t. The treatment of chronic renal disease. Med. Care 6, 48-54 (1968).
4. Manns B. J., Mendelssohn D. C. & Taub K. J. Th e economics of end-stage renal disease care in Canada: incentives and impact on delivery of care. Int. J. Health Care Finance Econ. 7, 149-169 (2007).
5. Hirth R. The organization and financing of kidney dialysis and transplant care i. The United States of America. Int. J. Health Care Finance Econ. 7, 301-318 (2007).
6. Rettig R. A. The social contract an. The treatment of permanent kidney failure. JAMA 275, 1123-1126 (1996).
7. United States Renal Data System. Annual Data Report 2002 Atlas of End-Stage Renal Disease i. The United States [online] http://www.usrds.org/atlas02.aspx 2002).
8. Ga rella S. The costs of dialysis i. The U.S.A. Nephrol. Dial. Transplant. 12 (Suppl. 1), 10-21 (1997).
9. Tomson C. R. Recent advances: nephrology. BMJ 320, 98-101 (2000).
10. Mallick N. P. The costs of renal services in Britain. Nephrol. Dial. Transplant. 12 (Suppl. 1), 25-28 (1997).
11. Grosse S. D. Assessing cost-effectiveness in healthcare: history o. The 50,000 per QALY threshold. Expert Rev. Pharmacoecon. Outcomes Res. 8, 165-178 (2008).
12. US Census Bureau. Historical National Population Estimates [online], http://www.census.gov/population/estimates/nation/popclockest.txt (2000).
13. Canadian Institute for Health Information. Canadian Organ Replacement Register Annual Report: Treatment of End-Stage Organ Failure in Canada, 2002 to 2011 [online], https://secure.cihi.ca/free-p roducts/2013-CORR-Annua-Report-EN.pdf (2013).
14. United States Renal Data System. Annual Data Report: 2010 Atlas of End-Stage Renal Disease i. The United States [online], http://www.usrds.org/atlas10.aspx (2012).
15. Moeller S., Gioberge S. & Brown G. ESRD patients in 2001: global overview of patients, treatment modalities and development trends. Nephrol. Dial. Transplant. 17, 2071-2076 (2002).
16. Jain A. K., Blake P., Cordy P. & Garg A. X. Global trends in rates of peritoneal dialysis. J. Am. Soc. Nephrol. 23, 533-544 (2012).
17. Wild S., Roglic G., Green A., Sicree R. & King H. Global prevalen ce of diabetes estimates fo. The year 2000 and projections for 2030. Diabetes Care 27, 1047-1053 (2004).
18. Rosansky S., Glassock R. J. & Clark W. F. Early start of dialysis: a critical review. Clin. J. Am. Soc. Nephrol. 6, 1222-1228 (2011).
19. Thomas B. A. et al. The rapidly growing global burden of end-stage renal disease-an analysis o. The change in maintenance dialysis prevalence bet ween 1990 and 2010. [Abstract]. J. Am. Soc. Nephrol. 32A (2013).
20. Donaldson C. & Shackley P. in Economic Evaluation (eds Detels R., Holland W. W., McEwan J. & Omenn G. S.) (Oxford University Press, 1997).
21. Klarenbach S. & Manns B. Economic evaluation of dialysis therapies. Semin. Nephrol. 29, 524-532 (2009).
22. Haller M. C., Vanholder R., Oberbauer R., Zoccali C. & Van Biesen W. Health economics and European Renal Best Practice-is it time to bring health economics into evidence-based guideline production in Europe? Nephrol. Dial. Transplant. http://dx.doi.org/10.1093/ndt/gft369.
23. Gerard K. & Mooney G. QALY league tables: handle with care. Health Econ. 2, 59-64 (1993).
24. Mauskopf J., Rutten F. & Schonfeld W. Cost-effectiveness league tables: valuable guidance for decision makers? Pharmacoeconomics 21, 991-1000 (2003).
25. Drummond M. F. Methods fo. The economic evaluation of health care programmes. (Oxford University Press, 1997).
26. Winkelmayer W. C., Weinstein M. C., Mittleman M. A., Glynn R. J. & Pliskin J. S. Health economic evaluations. The special case of end-stage renal disease treatment. Med. Decis. Making 22, 417-430 (2002).
27. Goeree R., Manalich J., Grootendorst P., Beecroft M. L. & Churchill D. N. Cost analysis of dialysis treatments for end-stage renal disease (ESRD). Clin. Invest. Med. 18, 455-464 (1995).
28. Lee H. et al. Cost analysis of ongoing care of patients with end-stage renal disease. The impact of dialysis modality and dialysis access. Am. J. Kidney Dis. 40, 611-622 (2002).
29. Chui B. K. et al Health care costs of peritoneal dialysis technique failure and dialysis modality switching. Am. J. Kidney Dis. 61 104-111 2013).
30. Shih Y. C., Guo A., Just P. M. & Mujais S. Impact of initial dialysis modality and modality switches on Medicare expenditures of end-stage renal disease patients. Kidney Int. 68, 319-329 (2005).
31. Karopadi A. N., Mason G., Rett ore E. & Ronco C. Cost of peritoneal dialysis and haemodialysis acros. The world. Nephrol. Dial. Transplant. 28, 2553-2569 (2013).
32. Cortes-Sanabria L. et al. Comparison of direct medical costs between automated and continuous ambulatory peritoneal dialysis. Perit. Dial. Int. 33, 679-686 (2013).
33. Liu F. X., Quock T. P., Burkart J., Noe L. L. & Inglese G. Economi c evaluations of peritoneal dialysis and hemodialysis: 2004-2012. F1000 Research 2, 273 (2013).
34. Korevaar J. C. et al. Effect of starting with hemodialysis compared with peritoneal dialysis in patients new on dialysis treatment: a randomized controlled trial. Kidney Int. 64, 2222-2228 (2003).
35. Lukowsky L. R. et al. Comparing mortality of peritoneal and hemodialysis patients i. The first 2 years of dialysis therapy: a marginal structural model analysis. Clin. J. Am. Soc. Nephrol. 8, 619-628 (2013).
36. Weinhandl E. D. et al. Propensity-matched mortality comparison of incident hemodialysis and peritoneal dialysis patients. J. Am. Soc. Nephrol. 21, 499-506 (2010).
37. Schaubel D. E., Morrison H. I. & Fenton S. S. Comparing mortality rates on CAPD/CCPD and hemodialysis. The Canadian experience: fact or fiction? Perit. Dial. Int. 18, 478-484 (1998).
38. Jaar B. G. et al. Comparin. The risk for death with p eritoneal dialysis and hemodialysis in a national cohort of patients with chronic kidney disease. Ann. Intern. Med. 143, 174-183 (2005).
39. Fenton S. S. et al. Hemodialysis versus peritoneal dialysis: a comparison of adjusted mortality rates. Am. J. Kidney Dis. 30, 334-342 (1997).
40. Foley R. N. et al. Mode of dialysis therapy and mortality in end-stage renal disease. J. Am. Soc. Nephrol. 9, 267-276 (1998).
41. Bloembergen W. E., Port F. K., Mauger E. A. & Wolfe R. A. A comparison of mortality between patients treated with hemodialysis and peritoneal dialysis. J. Am. Soc. Nephrol. 6, 177-183 (1995).
42. Collins A. J. et al. Mortality risks of peritoneal dialysis and hemodialysis. Am. J. Kidney Dis. 34, 1065-1074 (1999).
43. Klarenbach S. et al. Economic evaluation of frequent home nocturnal hemodialysis based on a randomized controlled trial. J. Am. Soc. Nephrol. 25, 587-594 (2014).
44. McFarlane P. A., Bayoumi A. M., Pierratos A. & Redelmeier D. A. The quality of life and cost utility of home nocturnal and conventional in-center hemodialysis. Kidney Int. 64, 1004-1011 (2003).
45. Kro eker A. et al. An operating cost comparison between conventional and home quotidian hemodialysis. Am. J. Kidney Dis. 42, 49-55 (2003).
46. Agar J. W. et al. Nocturnal haemodialysis: an Australian cost comparison with conventional satellite haemodialysis. Nephrology (Carlton) 10, 557-570 (2005).
47. McFarlane P. & Komenda P. Economic considerations in frequent home hemodialysis. Semin. Dial. 24, 678-683 (2011).
48. McFarlane P. A., Pierratos A. & Redelmeier D. A. Cost savings of home nocturnal versus conventional in-center hemodialysis. Kidney Int. 62, 2216-2222 (2002).
49. Canadian Agency for Drugs and Technologies in Health. Guidelines fo. The Economic Evaluation of Health Technologies: Canada 3rd Edition [online], http://www.cadth.ca/media/pdf/186-EconomicGuidelines-e.pdf ( 2006).
50. Lee C. P. Zenios S. A. Chertow G. M Cost-effectiveness of frequent in-center hemodialysis. J. Am. Soc. Nephrol.19 1792-1797 2008).
51. Cooper B. A. et al. A randomized, controlled trial of early versus late initiation of dialysis. N. Engl. J Med. 363, 609-619 (2010).
52. Harris A. et al. Cost-effectiveness of initiating dialysis early: a randomized controlled trial. Am. J. Kidney Dis. 57, 707-715 (2011).
53. Nesrallah G. E. et al. Canadian Society of Nephrology 2014 clinical practice guideline for timin. The initiation of chronic dialysis. CMAJ 186, 112-117 (2014).
54. Culleton B. F. et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controll ed trial. JAMA 298, 1291-1299 (2007).
55. Rocco M. V. et al. The effects of frequent nocturnal home hemodialysis. The Frequent Hemodialysis Network Nocturnal Trial. Kidney Int. 80, 1080-1091 (2011).
56. Mohr P. E. et al. The case for daily dialysis: its impact on costs and quality of life. Am. J. Kidney Dis. 37, 777-789 (2001).
57. Klarenbach S. W., Heidenheim A. P., Leitch R. & Lindsay R. M. Reduced requirement for erythropoietin with quotidian hemodialysis therapy. ASAIO J. 47, 153 (2001).
58. Wolfe R. A. et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N. Engl. J. Med. 341, 1725-1730 (1999).
59. Laupacis A. et al. A study o. The quality of life and cost-utility of renal transplantation. Kidney Int. 50, 235-242 (1996).
60. Whiting J. F. et al. Cost-effectiveness of organ donation: evaluating investment into donor action and other donor initiatives. Am. J. Transplant. 4, 569-573 (2004).
61. Barnieh L. et al. A description o. The costs of living and standard criteria deceased donor kidney transplantation. Am. J. Transplant. 11, 478-488 (2011).
62. Metzger R. A. et al. Expanded criteria donors for kidney transplantation. Am. J. Transplant. 3 (Suppl. 4), 114-125 (2003).
63. Bingaman A. W., Wright F. H. & Murphey C. L. Kidney paired donation in live-donor kidney transplantation. N. Engl. J. Med. 363, 1091-1092 (2010).
64. Park W. D. et al. Accommodation in ABO-incompatible kidney allografts, a novel mechanism of self-protection against antibody-mediated injury. Am. J. Transplant. 3, 952-960 (2003).
65. de Wit G. A., Ramsteijn P. G . & de Charro F. T. Economic evaluation of end stage renal disease treatment. Health Policy 44, 215-232 (1998).
66. Cueto-Manzano A. M. & Rojas-Campos E. Status of renal replacement therapy and peritoneal dialysis in Mexico. Perit. Dial. Int. 27, 142-148 (2007).
67. Canadian Institute for Health Information. Canadian Organ Replacement Register Annual Report: Treatment of End-Stage Organ Failure in Can ada, 2003 to 2012 [online], https://secure.cihi.ca/free-products/2014-CORR-Annual-Report-EN.pdf (2014).
68. United States Renal Data System. Annual Data Report: 2008 Atlas of Chronic Kidney Disease and End-Stage Renal Disease i. The United States [online], http://www.usrds.org/2008/view/default.asp (2008).
69. Neil N. et al. Gaining efficiencies: resources and demand for dialysis aroun. The globe. Value Health 12, 73-79 (2008).
70. Mendelssohn D. C. et al. A prospective evaluation of renal replacement therapy modality eligibility. Nephrol. Dial. Transplant. 24, 555-561 (2009).
71. Just P. M. et al Reimbursement and economic factors influencing dialysis modality choice aroun. The world. Nephrol. Dial. Transplant. 23 2365-2373 2008).
72. Chow K. M. & Li P. K.-T. Choice of dialysis-what to do with economic incentives. Nat. Rev. Nephrol. 8, 495-496 (2012).
73. Blagg C. R. Dialysis composite rate bundling: potential effects o. The utilization of home hemodialysis, daily and nocturnal hemodialysis, and peritoneal dialysis. Semin. Dial. 24, 674-677 (2011).
74. Li P. K.-T. & Chow K. M. Peritoneal dialysis-first policy made successful: perspectives and actions. Am. J. Kid. Dis. 62, 993-1005 (2013).
75. [No authors listed] Medical professionalism i. The new millennium: a physicians' charter. Lancet 9, 520-522 (2002).
76. International Monetary Fund. World Economic Outlook Database, April 2014: Report for Selected Countries and Subjects [online], http://www.imf.org/external/pubs/ft/weo/2014/01/weodata/index.aspx (2014).